Daniel Morgenstern, Staff Oncologist at Hospital for Sick Children, Toronto and Associate Professor at the University of Toronto, shared a post on LinkedIn:
“Delighted to announce that OPTIMISE Arm C is now open at our first Canadian site, The Hospital for Sick Children. This trial will evaluate a novel combined immune checkpoint inhibitor for paediatric patients with relapse/refractory solid tumours selected for high immune infiltration based on RNA sequencing data.
Many thanks to Stand Up To Cancer for supporting this initiative, building on pre-clinical and clinical work on use of immune checkpoint inhibitors in highly-mutated paediatric tumours with The International Replication Repair Deficiency Consortium (IRRDC).
Thanks to ANZCHOG, C17 Council, ACCESS-ACCES, Cancer Research Society for their support for Optimise.”
Other articles featuring Daniel Morgenstern on OncoDaily.